MARKET

FMTX

FMTX

Forma Therapeutics Holdings, Inc.,
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.72
-0.44
-1.73%
Opening 09:47 04/21 EDT
OPEN
25.10
PREV CLOSE
25.15
HIGH
25.20
LOW
24.50
VOLUME
9.74K
TURNOVER
--
52 WEEK HIGH
56.33
52 WEEK LOW
22.51
MARKET CAP
1.17B
P/E (TTM)
-12.5546
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 30)
Benzinga · 03/31 11:41
DJ Forma Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/31 10:35
DJ Forma Therapeutics Price Target Raised to $55.00/Share From $53.00 by HC Wainwright & Co.
Dow Jones · 03/31 10:35
10-K: FORMA THERAPEUTICS HOLDINGS, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/30 21:24
Cantor suggests buying Forma Therapeutics on weakness following sickle cell data
Cantor analyst Emma Nealon is maintaining her overweight rating and $68 price target on Forma Therapeutics (FMTX) despite weakness today on phase 1 results from its sickle cell candidate FT-4202.Those
Seekingalpha · 03/30 19:11
Forma Therapeutics High-Dose Of FT-4202 Numerically Inferior To Low Dose In Sickle Cell Disease Study
Forma Therapeutics Holdings Inc (NASDAQ: FMTX) has presented blinded data on sickle cell disease patients who received 600 mg of FT-4202, a pyruvate kinase R activator. The 600 mg high-dose cohort featured fewer hemoglobin responders than the 300-mg arm, b...
Benzinga · 03/30 16:08
DJ Forma Therapeutics Holdings, Inc. CEO Frank Lee on Q4 2020 Results -- Earnings Call Transcript >FMTX
Dow Jones · 03/30 15:27
The Daily Biotech Pulse: Wave Life Sciences Pulls Plug On 2 Assets, Amarin's Vascepa Snags European Approval, Biocept Jumps On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 29)
Benzinga · 03/30 12:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of FMTX. Analyze the recent business situations of Forma Therapeutics Holdings, Inc., through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average FMTX stock price target is 60.67 with a high estimate of 68.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 95
Institutional Holdings: 36.99M
% Owned: 78.10%
Shares Outstanding: 47.37M
TypeInstitutionsShares
Increased
33
7.12M
New
37
3.08M
Decreased
10
941.37K
Sold Out
4
26.56K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.24%
Key Executives
Non-Executive Chairman/Independent Director
Peter Wirth
President/Chief Executive Officer/Director
Frank Lee
Chief Financial Officer/Senior Vice President
Todd Shegog
Chief Human Resource Officer/Senior Vice President
Mary Wadlinger
Senior Vice President/Chief Scientific Officer
David Cook
Senior Vice President/General Counsel/Secretary
Jeannette Potts
Senior Vice President
Patrick Kelly
Director
Michael Foley
Director
Paolo Paoletti
Director
Michal Silverberg
Independent Director
Timothy Clackson
Independent Director
Marsha Fanucci
Independent Director
Steven Hall
Independent Director
Peter Kolchinsky
Independent Director
Selwyn Vickers
No Data
About FMTX
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for patients with rare hematologic diseases and cancers. Its pipeline consists of seven product candidates, two of which it is pursuing as core product candidates for development: FT-4202 for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Its other product candidate includes FT-2102 (Olutasidenib), FT-8225, FT-4101, CC-95775 and BI-1701963. FT-4202 is an oral, once-daily, potentially disease-modifying therapy. FT-4202 is a potent activator of pyruvate kinase-R (PKR), designed to improve RBC metabolism, function and survival, and potentially resulting in both increased hemoglobin levels and reduced VOCs. FT-7051, is a potent and selective inhibitor of CREB-binding protein/E1A binding protein p300 (CBP/p300).

Webull offers kinds of Forma Therapeutics Holdings Inc stock information, including NASDAQ:FMTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FMTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FMTX stock methods without spending real money on the virtual paper trading platform.